Biogen Shares Outstanding 2006-2021 | BIIB

Biogen shares outstanding history from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Biogen shares outstanding for the quarter ending September 30, 2021 were 0.149B, a 5.47% decline year-over-year.
  • Biogen 2020 shares outstanding were 0.161B, a 13.93% decline from 2019.
  • Biogen 2019 shares outstanding were 0.187B, a 8.72% decline from 2018.
  • Biogen 2018 shares outstanding were 0.205B, a 3.62% decline from 2017.
Biogen Annual Shares Outstanding
(Millions of Shares)
2020 161
2019 187
2018 205
2017 213
2016 219
2015 231
2014 237
2013 238
2012 240
2011 245
2010 255
2009 289
2008 295
2007 320
2006 345
2005 346
Biogen Quarterly Shares Outstanding
(Millions of Shares)
2021-09-30 149
2021-06-30 150
2021-03-31 152
2020-12-31 161
2020-09-30 157
2020-06-30 161
2020-03-31 173
2019-12-31 187
2019-09-30 184
2019-06-30 190
2019-03-31 197
2018-12-31 205
2018-09-30 202
2018-06-30 207
2018-03-31 212
2017-12-31 213
2017-09-30 212
2017-06-30 212
2017-03-31 216
2016-12-31 219
2016-09-30 219
2016-06-30 219
2016-03-31 219
2015-12-31 231
2015-09-30 233
2015-06-30 236
2015-03-31 236
2014-12-31 237
2014-09-30 237
2014-06-30 237
2014-03-31 238
2013-12-31 238
2013-09-30 238
2013-06-30 239
2013-03-31 238
2012-12-31 240
2012-09-30 238
2012-06-30 241
2012-03-31 242
2011-12-31 245
2011-09-30 245
2011-06-30 245
2011-03-31 245
2010-12-31 255
2010-09-30 242
2010-06-30 262
2010-03-31 273
2009-12-31 289
2009-09-30 291
2009-06-30 290
2009-03-31 290
2008-12-31 295
2008-09-30 294
2008-06-30 293
2008-03-31 300
2007-12-31 320
2007-09-30 293
2007-06-30 343
2007-03-31 344
2006-12-31 345
2006-09-30 345
2006-06-30 342
2006-03-31 346
2005-12-31 346
2005-09-30 341
2005-06-30 345
2005-03-31 352
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $32.393B $13.445B
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81